Biopolymer compositions comprising antimicrobial peptides (AMPs) for treating infections such as bacterial infections, viral infections, fungal infections, and parasitic infections. The compositions herein may also be used for treating infections associated with antibiotic-resistant bacteria, antifungal-resistant fungi, antiviral-resistant viruses, or for treating biological warfare agents (BWAs) such as Bacillus anthracis and Yersenia pestis. The present invention also provides methods of synthesis of said biopolymer compositions, wherein AMP biopolymers can be synthesized as an artificially engineered protein by genetically fusing an AMP; a protein that behaves similarly to polymer tethers; and a protein as a modifiable material platform that can transform to self-assembled nanoparticles, self-standing films, or adhesives to easily attach tethered AMPs onto any biomaterial surface for various clinical applications.

The invention provides a method for combating biofilm, said method comprising contacting a biofilm with a composition comprising an effective amount of antimicrobial peptide biofilm enzyme combinations, preferably in the form of a fusion protein. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides a composition for use in the treatment or prevention of a biofilm in a subject, particularly in the oral cavity.

The invention provides a method for combating biofilm, said method comprising contacting a biofilm with a composition comprising an effective amount of antimicrobial peptide biofilm enzyme combinations, preferably in the form of a fusion protein. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides a composition for use in the treatment or prevention of a biofilm in a subject, particularly in the oral cavity.

A method for treating a microbial infection in a subject includes administering to the subject a pharmaceutical composition which has a therapeutically effective amount of an antimicrobial peptide containing a derivative of P-113.

The present invention relates to the field of skin rejuvenation. Specifically, the present invention provides compositions and methods for promoting skin rejuvenation using a toll-like receptor 3 (TLR3) agonist and retinoic acid or derivatives thereof. In a specific embodiment, a method for treating wrinkles in a subject comprises the steps of (a) administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of retinoic acid or a derivative thereof; and administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of a TLR3 agonist.

The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues;
for use in the treatment of a tumour by combined, sequential or separate administration with an immune checkpoint inhibitor. The present invention further provides pharmaceutical packs or compositions comprising these active agents and methods of treating a tumour comprising administration of these active agents. Also provided are the peptidic compounds as defined above for use in the destabilisation of a mitochondrial membrane, and a peptidic compound as defined above and an immunotherapeutic agent as a combined preparation for separate, simultaneous or sequential use in treating tumours.

The present invention describes how a MAb specific to a viral or cancer antigen can be linked to a novel Zn porting peptide that is engineered to load ionic Zn absent requirement for biological catalysis, carry Zn stably through the circulation, release payload proximal to diseased cells, deliver its Zn cargo intracellularly due to ionophore activity, and release Zn intracellularly. As specifically designed for COVID-19, the payload can be released by furin cleavage, and the Zn released intracellularly by cleavage at a 3CL major COVID protease site replacing sequences naturally found in alpha defensin-5, as one example, or by many other variations encompassing this design. The peptide's entry and intracellular Zn release can be further facilitated by the insertion of an arginine-lysine rich membrane translocation sequence at its amino or carboxyl terminus. The design provides a novel unifying strategy for preventing and treating COVID-19 (SARS-CoV-2) infection, other coronaviral infections, influenza infections, and many cancers.

The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and
wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 μg of LL-37 applied per cm.sup.2 of wound area, and/or below about 26.7 μg of LL-37 applied per cm.sup.2 of wound area, per day of treatment.

The present application provides compounds, compositions and methods to reduce, alleviate or treat various enteric diseases and disorders, such as inflammatory bowel disease. The compounds are xyloglucan-containing prodrugs, referred to herein as glyco-caged prodrugs, of formula (I) or (II), xyloglucan-β-O—R.sup.D (I), xyloglucan-β-O-L.sup.SI-R.sup.D (II).

Treatments for synucleinopathy including Parkinson's Disease (PD), Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB) are largely unavailable. The invention provides methods for treating, preventing, inhibiting, and reversing synucleinopathy by attenuating MSH activity, decreasing MSH expression, or by modulating MSH engagement with its receptor by utilizing antagonists. Furthermore, the inventor has provided a method for producing a synucleinopathy animal model for screening treatments and for studying synuclein disease pathology.